Royalty Pharma plc (RPRX) 10-Year Financial Performance & Capital Metrics

RPRX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutRoyalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.Show more

Revenue $2.26B -3.9%
EBITDA $1.56B -17.5%
Net Income $859M -24.3%
EPS (Diluted) 1.91 -24.5%
Gross Margin 100%
EBITDA Margin 68.76% -14.2%
Operating Margin 57.1% -9.9%
Net Margin 37.95% -21.3%
ROE 8.41% -27.3%
ROIC 5.92% -18.9%
Debt/Equity 0.74 +21.0%
Interest Coverage 5.73 -28.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 122.3% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 32.2%
✓Trading near 52-week high

✗Weaknesses

✗Profits declining 18.2% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y4.52%

3Y-0.38%

TTM3.7%

Profit (Net Income) CAGR

10Y-

5Y-18.22%

3Y11.5%

TTM-33.2%

EPS CAGR

10Y-

5Y-22.03%

3Y8.63%

TTM-33.88%

ROCE

10Y Avg10.39%

5Y Avg7.83%

3Y Avg6.34%

Latest7.79%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.6B	1.79B	1.81B	2.12B	2.29B	2.24B	2.35B	2.26B
Revenue Growth %	-	0.12%	0.01%	0.17%	0.08%	-0.02%	0.05%	-0.04%
Cost of Goods Sold+	0	0	0	230.84M	0	0	0	0
COGS % of Revenue	-	-	-	0.11%	-	-	-	-
Gross Profit+	0	0	1.81B	1.89B	2.29B	2.24B	2.35B	2.26B
Gross Margin %	-	-	1%	0.89%	1%	1%	1%	1%
Gross Profit Growth %	-	-	-	0.04%	0.21%	-0.02%	0.05%	-0.04%
Operating Expenses+	658.24M	430.45M	-808.92M	296.12M	858.75M	1.93B	862.4M	971.13M
OpEx % of Revenue	0.41%	0.24%	-0.45%	0.14%	0.38%	0.86%	0.37%	0.43%
Selling, General & Admin	106.44M	61.91M	103.44M	181.72M	182.83M	227.3M	249.75M	236.67M
SG&A % of Revenue	0.07%	0.03%	0.06%	0.09%	0.08%	0.1%	0.11%	0.1%
Research & Development	117.87M	392.61M	83.04M	26.29M	200.08M	177.11M	52M	2M
R&D % of Revenue	0.07%	0.22%	0.05%	0.01%	0.09%	0.08%	0.02%	0%
Other Operating Expenses	433.93M	-24.07M	-995.4M	88.11M	475.84M	1.53B	560.66M	732.46M
Operating Income+	939.69M	1.36B	2.62B	1.6B	1.43B	307.06M	1.49B	1.29B
Operating Margin %	0.59%	0.76%	1.45%	0.75%	0.62%	0.14%	0.63%	0.57%
Operating Income Growth %	-	0.45%	0.92%	-0.39%	-0.1%	-0.79%	3.86%	-0.13%
EBITDA+	972.96M	1.4B	2.65B	1.62B	1.45B	312.74M	1.89B	1.56B
EBITDA Margin %	0.61%	0.78%	1.46%	0.76%	0.63%	0.14%	0.8%	0.69%
EBITDA Growth %	-	0.44%	0.89%	-0.39%	-0.1%	-0.78%	5.03%	-0.18%
D&A (Non-Cash Add-back)	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0
EBIT	1.59B	1.8B	2.73B	1.66B	1.41B	418.02M	1.89B	1.56B
Net Interest Income+	-240.58M	-255.51M	-246.24M	-128.68M	-112.61M	-109.63M	-114.9M	-178.17M
Interest Income	6.76M	24.44M	22.33M	28.38M	53.53M	78.33M	72.29M	47.34M
Interest Expense	247.34M	279.96M	268.57M	157.06M	166.14M	187.96M	187.19M	225.51M
Other Income/Expense	403.49M	153.41M	-161.76M	106.56M	-189.51M	-77M	207.94M	38.37M
Pretax Income+	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Pretax Margin %	0.84%	0.85%	1.36%	0.8%	0.54%	0.1%	0.72%	0.59%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.9%	0.91%	0.95%	0.57%	0.5%	0.19%	0.67%	0.65%
Net Income+	1.21B	1.38B	2.35B	975.04M	619.73M	42.83M	1.13B	858.98M
Net Margin %	0.76%	0.77%	1.29%	0.46%	0.27%	0.02%	0.48%	0.38%
Net Income Growth %	-	0.14%	0.7%	-0.58%	-0.36%	-0.93%	25.5%	-0.24%
Net Income (Continuing)	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B
EPS (Diluted)+	3.42	3.89	6.63	2.51	1.49	0.10	2.53	1.91
EPS Growth %	-	0.14%	0.7%	-0.62%	-0.41%	-0.93%	24.3%	-0.25%
EPS (Basic)	3.42	3.89	6.63	2.51	1.49	0.10	2.54	1.92
Diluted Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.8M	437.97M	602.9M	594M
Basic Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.79M	437.96M	447.6M	445.99M
Dividend Payout Ratio	0.61%	0.59%	0.31%	0.41%	0.46%	7.78%	0.32%	0.44%

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.95B	2.61B	832.07M	2.7B	2.88B	2.55B	1.27B	1.8B
Cash & Short-Term Investments	1.38B	2.39B	793.21M	2.65B	2.8B	2.43B	1.23B	1.77B
Cash Only	1.38B	1.92B	246.2M	1.01B	1.54B	1.71B	477.01M	929.03M
Short-Term Investments	0	461.82M	547.01M	1.64B	1.26B	717.04M	756.74M	841.97M
Accounts Receivable	0	198.63M	38.77M	39.17M	68.31M	36.6M	22.41M	26.96M
Days Sales Outstanding	-	40.39	7.8	6.74	10.89	5.97	3.47	4.35
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	1.57B	23.89M	92K	8.6M	6.63M	90.52M	18.04M	4.19M
Total Non-Current Assets+	8.43B	8.76B	11.62B	13.32B	14.64B	14.26B	15.11B	16.42B
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	75.65M	51.72M	28.67M	5.67M	0	0	15.13B
Long-Term Investments	0	8.67B	11.48B	13.28B	14.63B	14.23B	15.1B	16.39B
Other Non-Current Assets	0	19.11M	87.95M	10M	4.14M	29.63M	6.52M	-15.09B
Total Assets+	11.37B	11.37B	12.45B	16.02B	17.52B	16.81B	16.38B	18.22B
Asset Turnover	0.14x	0.16x	0.15x	0.13x	0.13x	0.13x	0.14x	0.12x
Asset Growth %	-	-0%	0.09%	0.29%	0.09%	-0.04%	-0.03%	0.11%
Total Current Liabilities+	383.41M	580.17M	333.42M	307.89M	171.25M	1.17B	161.38M	1.25B
Accounts Payable	0	4.48M	11.18M	10.78M	5.62M	7.91M	15.16M	13.37M
Days Payables Outstanding	-	-	-	17.04	-	-	-	-
Short-Term Debt	280.93M	281.44M	281.98M	0	0	997.51M	0	997.77M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	102.48M	0	9.21M	18.6M	0	12.4M	11.38M	68.6M
Current Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x
Quick Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.52B	6.24B	5.98B	5.82B	7.1B	6.12B	6.14B	6.63B
Long-Term Debt	6.52B	6.24B	5.96B	5.82B	7.1B	6.12B	6.14B	6.61B
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	18.9M	0	0	2.5M	900K	12.08M
Total Liabilities	6.9B	6.82B	6.31B	6.12B	7.27B	7.29B	6.3B	7.88B
Total Debt+	6.8B	6.52B	6.24B	5.82B	7.1B	7.12B	6.14B	7.61B
Net Debt	5.42B	4.6B	5.99B	4.81B	5.56B	5.41B	5.66B	6.68B
Debt / Equity	1.52x	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x
Debt / EBITDA	6.99x	4.66x	2.36x	3.59x	4.88x	22.76x	3.25x	4.89x
Net Debt / EBITDA	5.57x	3.29x	2.26x	2.97x	3.82x	17.28x	3.00x	4.29x
Interest Coverage	3.80x	4.87x	9.77x	10.16x	8.61x	1.63x	7.97x	5.73x
Total Equity+	4.46B	4.55B	6.14B	9.9B	10.25B	9.53B	10.08B	10.34B
Equity Growth %	-	0.02%	0.35%	0.61%	0.04%	-0.07%	0.06%	0.03%
Book Value per Share	12.59	12.85	17.34	25.50	24.71	21.75	16.73	17.41
Total Shareholders' Equity	4.46B	4.49B	6.11B	4.82B	5.78B	5.63B	6.53B	6.95B
Common Stock	0	3.28B	3.28B	102K	106K	107K	108K	108K
Retained Earnings	0	1.22B	2.83B	1.92B	2.26B	1.96B	2.52B	2.85B
Treasury Stock	0	0	-4.27M	-2.32M	-2.71M	-2.81M	-2.63M	-2.66M
Accumulated OCI	0	-10.26M	2.09M	34.4M	16.49M	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.42B	1.62B	1.67B	2.03B	2.02B	2.14B	2.99B	2.77B
Operating CF Margin %	0.89%	0.9%	0.92%	0.96%	0.88%	0.96%	1.27%	1.22%
Operating CF Growth %	-	0.14%	0.03%	0.22%	-0.01%	0.06%	0.39%	-0.07%
Net Income	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Depreciation & Amortization	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0
Stock-Based Compensation	0	0	0	5.43M	2.44M	2.17M	2.36M	2.34M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.52B	1.63B	-793.43M	228.22M	767.22M	1.87B	1.28B	1.38B
Working Capital Changes	-1.48B	-1.56B	-24.67M	75.97M	-16.32M	32.66M	5.38M	53.38M
Change in Receivables	-84.48M	111.53M	159.86M	-400K	-29.14M	-4.74M	-1.52M	-4.55M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	1.35M	6.5M	-766K	-4.59M	2.29M	6.24M	-2.29M
Cash from Investing+	-1.59B	303.42M	-2.15B	-2.76B	-1.87B	-1.03B	-2.07B	-2.68B
Capital Expenditures	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	115M	0	-250M	15.08M	-18.08M	0	29.44M	-49.32M
Cash from Financing+	-123.25M	-1.38B	-1.19B	1.49B	385.11M	-944.86M	-2.15B	361.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	-735.17M	-814.36M	-739.28M	-397.84M	-285.18M	-333.32M	-358.33M	-376.46M
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	-295.08M	-270.74M	-154.08M	-704.36M	-602.24M	-611.53M	-485.67M	-503.97M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	1.42B	1.62B	1.67B	2.03B	2.02B	2.14B	2.99B	2.77B
FCF Margin %	0.89%	0.9%	0.92%	0.96%	0.88%	0.96%	1.27%	1.22%
FCF Growth %	-	0.14%	0.03%	0.22%	-0.01%	0.06%	0.39%	-0.07%
FCF per Share	4.00	4.57	4.71	5.24	4.86	4.90	4.96	4.66
FCF Conversion (FCF/Net Income)	1.17x	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	27.13%	30.57%	43.92%	12.16%	6.15%	0.43%	11.57%	8.41%
Return on Invested Capital (ROIC)	-	10.76%	18.49%	8.92%	7.03%	1.5%	7.3%	5.92%
Gross Margin	-	-	100%	89.12%	100%	100%	100%	100%
Net Margin	75.72%	76.76%	129.45%	45.94%	27.07%	1.91%	48.2%	37.95%
Debt / Equity	1.52x	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x
Interest Coverage	3.80x	4.87x	9.77x	10.16x	8.61x	1.63x	7.97x	5.73x
FCF Conversion	1.17x	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x
Revenue Growth	-	12.33%	1.08%	16.98%	7.87%	-2.28%	5.24%	-3.86%

Revenue by Segment

	2020	2021	2022	2023	2024
Financial Royalty Assets	1.96B	2.07B	2.13B	2.2B	2.15B
Financial Royalty Assets Growth	-	5.36%	2.91%	3.42%	-2.20%
Royalty Income, Other	19M	53.13M	74.64M	155.97M	114.15M
Royalty Income, Other Growth	-	179.70%	40.47%	108.97%	-26.81%
Intangible Royalty Assets	143.38M	171.25M	37.48M	835K	-
Intangible Royalty Assets Growth	-	19.43%	-78.11%	-97.77%	-

Frequently Asked Questions

Valuation & Price

Royalty Pharma plc (RPRX) has a price-to-earnings (P/E) ratio of 20.8x. This is roughly in line with market averages.

Growth & Financials

Royalty Pharma plc (RPRX) reported $2.35B in revenue for fiscal year 2024. This represents a 47% increase from $1.60B in 2017.

Royalty Pharma plc (RPRX) saw revenue decline by 3.9% over the past year.

Yes, Royalty Pharma plc (RPRX) is profitable, generating $765.0M in net income for fiscal year 2024 (37.9% net margin).

Dividend & Returns

Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.60%. This makes it attractive for income-focused investors.

Royalty Pharma plc (RPRX) has a return on equity (ROE) of 8.4%. This is below average, suggesting room for improvement.

Royalty Pharma plc (RPRX) generated $2.41B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Royalty Pharma plc (RPRX) 10-Year Financial Performance & Capital Metrics

RPRX • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $2.26B -3.9%
EBITDA $1.56B -17.5%
Net Income $859M -24.3%
EPS (Diluted) 1.91 -24.5%
Gross Margin 100%
EBITDA Margin 68.76% -14.2%
Operating Margin 57.1% -9.9%
Net Margin 37.95% -21.3%
ROE 8.41% -27.3%
ROIC 5.92% -18.9%
Debt/Equity 0.74 +21.0%
Interest Coverage 5.73 -28.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 122.3% free cash flow margin
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 32.2%
✓Trading near 52-week high

✗Weaknesses

✗Profits declining 18.2% over 5 years
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y4.52%

3Y-0.38%

TTM3.7%

Profit (Net Income) CAGR

10Y-

5Y-18.22%

3Y11.5%

TTM-33.2%

EPS CAGR

10Y-

5Y-22.03%

3Y8.63%

TTM-33.88%

ROCE

10Y Avg10.39%

5Y Avg7.83%

3Y Avg6.34%

Latest7.79%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.6B	1.79B	1.81B	2.12B	2.29B	2.24B	2.35B	2.26B
Revenue Growth %	-	0.12%	0.01%	0.17%	0.08%	-0.02%	0.05%	-0.04%
Cost of Goods Sold+	0	0	0	230.84M	0	0	0	0
COGS % of Revenue	-	-	-	0.11%	-	-	-	-
Gross Profit+	0	0	1.81B	1.89B	2.29B	2.24B	2.35B	2.26B
Gross Margin %	-	-	1%	0.89%	1%	1%	1%	1%
Gross Profit Growth %	-	-	-	0.04%	0.21%	-0.02%	0.05%	-0.04%
Operating Expenses+	658.24M	430.45M	-808.92M	296.12M	858.75M	1.93B	862.4M	971.13M
OpEx % of Revenue	0.41%	0.24%	-0.45%	0.14%	0.38%	0.86%	0.37%	0.43%
Selling, General & Admin	106.44M	61.91M	103.44M	181.72M	182.83M	227.3M	249.75M	236.67M
SG&A % of Revenue	0.07%	0.03%	0.06%	0.09%	0.08%	0.1%	0.11%	0.1%
Research & Development	117.87M	392.61M	83.04M	26.29M	200.08M	177.11M	52M	2M
R&D % of Revenue	0.07%	0.22%	0.05%	0.01%	0.09%	0.08%	0.02%	0%
Other Operating Expenses	433.93M	-24.07M	-995.4M	88.11M	475.84M	1.53B	560.66M	732.46M
Operating Income+	939.69M	1.36B	2.62B	1.6B	1.43B	307.06M	1.49B	1.29B
Operating Margin %	0.59%	0.76%	1.45%	0.75%	0.62%	0.14%	0.63%	0.57%
Operating Income Growth %	-	0.45%	0.92%	-0.39%	-0.1%	-0.79%	3.86%	-0.13%
EBITDA+	972.96M	1.4B	2.65B	1.62B	1.45B	312.74M	1.89B	1.56B
EBITDA Margin %	0.61%	0.78%	1.46%	0.76%	0.63%	0.14%	0.8%	0.69%
EBITDA Growth %	-	0.44%	0.89%	-0.39%	-0.1%	-0.78%	5.03%	-0.18%
D&A (Non-Cash Add-back)	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0
EBIT	1.59B	1.8B	2.73B	1.66B	1.41B	418.02M	1.89B	1.56B
Net Interest Income+	-240.58M	-255.51M	-246.24M	-128.68M	-112.61M	-109.63M	-114.9M	-178.17M
Interest Income	6.76M	24.44M	22.33M	28.38M	53.53M	78.33M	72.29M	47.34M
Interest Expense	247.34M	279.96M	268.57M	157.06M	166.14M	187.96M	187.19M	225.51M
Other Income/Expense	403.49M	153.41M	-161.76M	106.56M	-189.51M	-77M	207.94M	38.37M
Pretax Income+	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Pretax Margin %	0.84%	0.85%	1.36%	0.8%	0.54%	0.1%	0.72%	0.59%
Income Tax+	0	0	0	0	0	0	0	0
Effective Tax Rate %	0.9%	0.91%	0.95%	0.57%	0.5%	0.19%	0.67%	0.65%
Net Income+	1.21B	1.38B	2.35B	975.04M	619.73M	42.83M	1.13B	858.98M
Net Margin %	0.76%	0.77%	1.29%	0.46%	0.27%	0.02%	0.48%	0.38%
Net Income Growth %	-	0.14%	0.7%	-0.58%	-0.36%	-0.93%	25.5%	-0.24%
Net Income (Continuing)	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Discontinued Operations	0	0	0	0	0	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B
EPS (Diluted)+	3.42	3.89	6.63	2.51	1.49	0.10	2.53	1.91
EPS Growth %	-	0.14%	0.7%	-0.62%	-0.41%	-0.93%	24.3%	-0.25%
EPS (Basic)	3.42	3.89	6.63	2.51	1.49	0.10	2.54	1.92
Diluted Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.8M	437.97M	602.9M	594M
Basic Shares Outstanding	354.18M	354.18M	354.18M	388.13M	414.79M	437.96M	447.6M	445.99M
Dividend Payout Ratio	0.61%	0.59%	0.31%	0.41%	0.46%	7.78%	0.32%	0.44%

Balance Sheet

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.95B	2.61B	832.07M	2.7B	2.88B	2.55B	1.27B	1.8B
Cash & Short-Term Investments	1.38B	2.39B	793.21M	2.65B	2.8B	2.43B	1.23B	1.77B
Cash Only	1.38B	1.92B	246.2M	1.01B	1.54B	1.71B	477.01M	929.03M
Short-Term Investments	0	461.82M	547.01M	1.64B	1.26B	717.04M	756.74M	841.97M
Accounts Receivable	0	198.63M	38.77M	39.17M	68.31M	36.6M	22.41M	26.96M
Days Sales Outstanding	-	40.39	7.8	6.74	10.89	5.97	3.47	4.35
Inventory	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-
Other Current Assets	1.57B	23.89M	92K	8.6M	6.63M	90.52M	18.04M	4.19M
Total Non-Current Assets+	8.43B	8.76B	11.62B	13.32B	14.64B	14.26B	15.11B	16.42B
Property, Plant & Equipment	0	0	0	0	0	0	0	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0
Intangible Assets	0	75.65M	51.72M	28.67M	5.67M	0	0	15.13B
Long-Term Investments	0	8.67B	11.48B	13.28B	14.63B	14.23B	15.1B	16.39B
Other Non-Current Assets	0	19.11M	87.95M	10M	4.14M	29.63M	6.52M	-15.09B
Total Assets+	11.37B	11.37B	12.45B	16.02B	17.52B	16.81B	16.38B	18.22B
Asset Turnover	0.14x	0.16x	0.15x	0.13x	0.13x	0.13x	0.14x	0.12x
Asset Growth %	-	-0%	0.09%	0.29%	0.09%	-0.04%	-0.03%	0.11%
Total Current Liabilities+	383.41M	580.17M	333.42M	307.89M	171.25M	1.17B	161.38M	1.25B
Accounts Payable	0	4.48M	11.18M	10.78M	5.62M	7.91M	15.16M	13.37M
Days Payables Outstanding	-	-	-	17.04	-	-	-	-
Short-Term Debt	280.93M	281.44M	281.98M	0	0	997.51M	0	997.77M
Deferred Revenue (Current)	0	0	0	0	0	0	0	0
Other Current Liabilities	102.48M	0	9.21M	18.6M	0	12.4M	11.38M	68.6M
Current Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x
Quick Ratio	7.69x	4.50x	2.50x	8.76x	16.81x	2.19x	7.90x	1.44x
Cash Conversion Cycle	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	6.52B	6.24B	5.98B	5.82B	7.1B	6.12B	6.14B	6.63B
Long-Term Debt	6.52B	6.24B	5.96B	5.82B	7.1B	6.12B	6.14B	6.61B
Capital Lease Obligations	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	18.9M	0	0	2.5M	900K	12.08M
Total Liabilities	6.9B	6.82B	6.31B	6.12B	7.27B	7.29B	6.3B	7.88B
Total Debt+	6.8B	6.52B	6.24B	5.82B	7.1B	7.12B	6.14B	7.61B
Net Debt	5.42B	4.6B	5.99B	4.81B	5.56B	5.41B	5.66B	6.68B
Debt / Equity	1.52x	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x
Debt / EBITDA	6.99x	4.66x	2.36x	3.59x	4.88x	22.76x	3.25x	4.89x
Net Debt / EBITDA	5.57x	3.29x	2.26x	2.97x	3.82x	17.28x	3.00x	4.29x
Interest Coverage	3.80x	4.87x	9.77x	10.16x	8.61x	1.63x	7.97x	5.73x
Total Equity+	4.46B	4.55B	6.14B	9.9B	10.25B	9.53B	10.08B	10.34B
Equity Growth %	-	0.02%	0.35%	0.61%	0.04%	-0.07%	0.06%	0.03%
Book Value per Share	12.59	12.85	17.34	25.50	24.71	21.75	16.73	17.41
Total Shareholders' Equity	4.46B	4.49B	6.11B	4.82B	5.78B	5.63B	6.53B	6.95B
Common Stock	0	3.28B	3.28B	102K	106K	107K	108K	108K
Retained Earnings	0	1.22B	2.83B	1.92B	2.26B	1.96B	2.52B	2.85B
Treasury Stock	0	0	-4.27M	-2.32M	-2.71M	-2.81M	-2.63M	-2.66M
Accumulated OCI	0	-10.26M	2.09M	34.4M	16.49M	0	0	0
Minority Interest	0	63.87M	35.88M	5.08B	4.47B	3.9B	3.56B	3.4B

Cash Flow

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	1.42B	1.62B	1.67B	2.03B	2.02B	2.14B	2.99B	2.77B
Operating CF Margin %	0.89%	0.9%	0.92%	0.96%	0.88%	0.96%	1.27%	1.22%
Operating CF Growth %	-	0.14%	0.03%	0.22%	-0.01%	0.06%	0.39%	-0.07%
Net Income	1.34B	1.52B	2.46B	1.7B	1.24B	230.06M	1.7B	1.33B
Depreciation & Amortization	33.27M	33.27M	23.92M	23.06M	23M	5.67M	0	0
Stock-Based Compensation	0	0	0	5.43M	2.44M	2.17M	2.36M	2.34M
Deferred Taxes	0	0	0	0	0	0	0	0
Other Non-Cash Items	1.52B	1.63B	-793.43M	228.22M	767.22M	1.87B	1.28B	1.38B
Working Capital Changes	-1.48B	-1.56B	-24.67M	75.97M	-16.32M	32.66M	5.38M	53.38M
Change in Receivables	-84.48M	111.53M	159.86M	-400K	-29.14M	-4.74M	-1.52M	-4.55M
Change in Inventory	0	0	0	0	0	0	0	0
Change in Payables	0	1.35M	6.5M	-766K	-4.59M	2.29M	6.24M	-2.29M
Cash from Investing+	-1.59B	303.42M	-2.15B	-2.76B	-1.87B	-1.03B	-2.07B	-2.68B
Capital Expenditures	0	0	0	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-
Other Investing	115M	0	-250M	15.08M	-18.08M	0	29.44M	-49.32M
Cash from Financing+	-123.25M	-1.38B	-1.19B	1.49B	385.11M	-944.86M	-2.15B	361.14M
Debt Issued (Net)	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-
Dividends Paid	-735.17M	-814.36M	-739.28M	-397.84M	-285.18M	-333.32M	-358.33M	-376.46M
Share Repurchases	-	-	-	-	-	-	-	-
Other Financing	-295.08M	-270.74M	-154.08M	-704.36M	-602.24M	-611.53M	-485.67M	-503.97M
Net Change in Cash	-	-	-	-	-	-	-	-
Free Cash Flow+	1.42B	1.62B	1.67B	2.03B	2.02B	2.14B	2.99B	2.77B
FCF Margin %	0.89%	0.9%	0.92%	0.96%	0.88%	0.96%	1.27%	1.22%
FCF Growth %	-	0.14%	0.03%	0.22%	-0.01%	0.06%	0.39%	-0.07%
FCF per Share	4.00	4.57	4.71	5.24	4.86	4.90	4.96	4.66
FCF Conversion (FCF/Net Income)	1.17x	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x
Interest Paid	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0

Key Ratios

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	27.13%	30.57%	43.92%	12.16%	6.15%	0.43%	11.57%	8.41%
Return on Invested Capital (ROIC)	-	10.76%	18.49%	8.92%	7.03%	1.5%	7.3%	5.92%
Gross Margin	-	-	100%	89.12%	100%	100%	100%	100%
Net Margin	75.72%	76.76%	129.45%	45.94%	27.07%	1.91%	48.2%	37.95%
Debt / Equity	1.52x	1.43x	1.02x	0.59x	0.69x	0.75x	0.61x	0.74x
Interest Coverage	3.80x	4.87x	9.77x	10.16x	8.61x	1.63x	7.97x	5.73x
FCF Conversion	1.17x	1.17x	0.71x	2.09x	3.26x	50.06x	2.63x	3.22x
Revenue Growth	-	12.33%	1.08%	16.98%	7.87%	-2.28%	5.24%	-3.86%

Revenue by Segment

	2020	2021	2022	2023	2024
Financial Royalty Assets	1.96B	2.07B	2.13B	2.2B	2.15B
Financial Royalty Assets Growth	-	5.36%	2.91%	3.42%	-2.20%
Royalty Income, Other	19M	53.13M	74.64M	155.97M	114.15M
Royalty Income, Other Growth	-	179.70%	40.47%	108.97%	-26.81%
Intangible Royalty Assets	143.38M	171.25M	37.48M	835K	-
Intangible Royalty Assets Growth	-	19.43%	-78.11%	-97.77%	-

Frequently Asked Questions

Valuation & Price

Royalty Pharma plc (RPRX) has a price-to-earnings (P/E) ratio of 20.8x. This is roughly in line with market averages.

Growth & Financials

Royalty Pharma plc (RPRX) reported $2.35B in revenue for fiscal year 2024. This represents a 47% increase from $1.60B in 2017.

Royalty Pharma plc (RPRX) saw revenue decline by 3.9% over the past year.

Yes, Royalty Pharma plc (RPRX) is profitable, generating $765.0M in net income for fiscal year 2024 (37.9% net margin).

Dividend & Returns

Yes, Royalty Pharma plc (RPRX) pays a dividend with a yield of 1.60%. This makes it attractive for income-focused investors.

Royalty Pharma plc (RPRX) has a return on equity (ROE) of 8.4%. This is below average, suggesting room for improvement.

Royalty Pharma plc (RPRX) generated $2.41B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.